You are here:

dalteparin (Fragmin)


following a full submission

dalteparin (Fragmin®) is accepted for restricted use within NHS Scotland.

Indication under review: extended treatment of symptomatic venous thromboembolism (VTE) and prevention of its recurrence in patients with solid tumours.

SMC restriction: initiation by healthcare professionals experienced in the treatment of VTE.

In patients with cancer and VTE, dalteparin significantly reduced the rates of VTE recurrence over a six month period, compared to oral anticoagulation. Bleeding and mortality rates for patients receiving dalteparin were similar to those reported in patients receiving oral anticoagulant.

The economic case was demonstrated for dalteparin compared to other low molecular weight heparins.

Drug Details

Drug Name: dalteparin (Fragmin)
SMC Drug ID: 683/11
Manufacturer: Pfizer Ltd
Indication: Patients with solid tumours: extended treatment of symptomatic VTE and prevention of recurrence.
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Restricted
Date Advice Published: 7 March 2011